Immunomedics of Morris Plains, NJ, last week announced that ithas received clearance from the European Commission to marketits CEA-Scan colorectal cancer imaging agent in the 15 countriesof the European Union. The monoclonal-antibody-based agent
Immunomedics of Morris Plains, NJ, last week announced that it
has received clearance from the European Commission to market
its CEA-Scan colorectal cancer imaging agent in the 15 countries
of the European Union. The monoclonal-antibody-based agent received
U.S. clearance in June (SCAN 7/17/96). Mallinckrodt Medical of
St. Louis has marketing rights to CEA-Scan in both the U.S. and
Europe.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.